MannKind (MNKD +2%) announces additional data on Afrezza (insulin human) Inhalation Powder being presented this week at the Annual Scientific and Clinical Congress of he American Association of Clinical Endocrinologists in Los Angeles.
Compared to Eli Lilly’s (LLY -0.5%) Humalog (insulin lispro injection), Afrezza delivered better control of early post-prandial (after a meal) glucose levels in a dose-dependent manner. It was also associated with lower postprandial glucagon and C-peptide levels while producing faster decreases in free fatty acid levels.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.